论文部分内容阅读
目的探讨血清肿瘤标记物CEA、CA125、CYFR211、NSE联合检测对肺癌的早期诊断价值。方法选取肺癌患者80例(肺癌组)。健康体检者80例(对照组)。空腹釆血5ml,采用Rche电化学发光法和酶联免疫吸附法(ELZSA),检查80例肺癌患者和80例健康体健患者,血清肿瘤标记物CEA、CA125、CYFR211、NSE水平。结果健康体检与肺癌组四项指标比较差异有统计学意义(P<0.01)。肺癌患者肿瘤标记物CEA、CA125、CYFR211、NSE检测的阳性率(%)分别为62.5%(50/80)、65%(52/80)、67.5%(54/80)、85%(68/80)。四项指标联合检测的阳性率为90%(72/80)健康体检组的四项指标未检测出一例阳性者。结论血清肿瘤标记物抗原CEA、CA125、CYFR211、NSE联合检测水平可作为诊断肺癌的一项有价值的指标。
Objective To investigate the value of serum tumor markers CEA, CA125, CYFR211 and NSE in the early diagnosis of lung cancer. Methods 80 patients with lung cancer (lung cancer group) were selected. 80 healthy subjects (control group). Fasting blood 5ml, using Rche electrochemiluminescence and enzyme-linked immunosorbent assay (ELZSA), 80 cases of lung cancer patients and 80 healthy healthy patients, serum tumor markers CEA, CA125, CYFR211, NSE levels. Results There were significant differences among the four indexes in healthy physical examination and lung cancer group (P <0.01). The positive rates of tumor markers CEA, CA125, CYFR211 and NSE in patients with lung cancer were 62.5% (50/80), 65% (52/80), 67.5% (54/80) and 85% (68% 80). The positive rate of joint detection of four indicators was 90% (72/80). No positive result was detected in the four indicators of the health examination group. Conclusion Serum tumor marker antigen CEA, CA125, CYFR211, NSE combined detection level can be used as a valuable indicator of lung cancer diagnosis.